Virus vs. superbug: experimental therapy targets Drug-Resistant lung infection
NCT ID NCT07228702
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a special virus called a bacteriophage, combined with standard antibiotics, to treat a severe lung infection caused by Mycobacterium abscessus. The trial involves just one patient and aims to see if the virus can help clear the infection. It is an early, personalized approach for a condition that is very hard to treat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mycobacteriophage Muddy_HRMN0052 (a virus that attacks bacteria) plus standard antibiotics (amikacin, clofazimine, bedaquiline, linezolid)
What this could lead to
If it works, this could point toward a new treatment option for people with stubborn lung infections that don't respond to standard antibiotics.
What could go wrong
This is a very early study in just one person, so results may not apply to others. The treatment may not work, and there are risks from both the phage and the strong antibiotics.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-TUBERCULOUS MYCOBACTERIAL (NTM) PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic
Vancouver, British Columbia, V5Z 1M9, Canada